Biologics Manufacturing Market: Regional Trends and Growth Opportunities

The global biologics manufacturing market was valued at USD 33.48 billion in 2024 and is projected to reach USD 140.62 billion by 2033, growing at a CAGR of 17.0% from 2025 to 2033. This robust growth is driven by the rising demand for biopharmaceuticals, expansion of biologics production capabilities, and rapid advancements in cell and gene therapy manufacturing technologies.

Growing demand for targeted and innovative therapies continues to propel the market. Biologics—including monoclonal antibodies, antibody-drug conjugates, and cell and gene therapies—offer precise mechanisms that address the molecular origins of diseases. Their ability to improve treatment efficacy while reducing adverse effects makes them essential for managing conditions such as cancer, autoimmune disorders, and rare genetic diseases. As a result, biopharmaceutical and biotechnology companies are significantly ramping up investments in R&D pipelines to introduce next-generation biologics.

Key Market Trends & Insights

• North America held the largest share of the global market in 2024, at 41.78%.
• The U.S. biologics manufacturing market is expected to grow substantially through 2033.
• By mode of manufacturing, contract manufacturing accounted for the highest market share in 2024.
• By modality, monoclonal antibodies (mAbs) dominated the market with a 40.37% share in 2024.
• By disease indication, the oncology segment held the highest market share in 2024.

Download a free sample PDF of the Biologics Manufacturing Market Intelligence Study by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 33.48 Billion
• 2033 Projected Market Size: USD 140.62 Billion
• CAGR (2025–2033): 17.0%
• Largest Market (2024): North America
• Fastest-Growing Region: Asia Pacific

Competitive Landscape

The biologics manufacturing landscape is led by well-established biopharmaceutical companies with extensive product pipelines, large-scale production capabilities, and global distribution networks. Major players such as Novartis AG, Pfizer Inc., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd. continue to capture significant market share through continuous innovation and substantial R&D investments.

Specialized contract development and manufacturing organizations (CDMOs) are also expanding their presence. Companies including WuXi Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, Lonza, and Samsung Biologics offer flexible and scalable solutions spanning monoclonal antibodies, recombinant proteins, vaccines, and advanced cell and gene therapies. Their end-to-end capabilities support both emerging biotech firms and large pharmaceutical companies.

Market leaders maintain their competitive edge through the integration of advanced bioprocessing technologies—such as single-use systems, continuous manufacturing, and next-generation cell culture platforms—coupled with global expansion strategies and strong regulatory compliance frameworks. These efforts significantly reduce time-to-market for innovative therapeutics and enhance manufacturing efficiency.

Prominent Companies

• Novartis AG
• Pfizer Inc.
• Amgen Inc.
• Novo Nordisk A/S
• AbbVie Inc.
• Johnson & Johnson (Johnson & Johnson Services, Inc.)
• Bristol-Myers Squibb Company
• Eli Lilly and Company

Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.

Conclusion

The biologics manufacturing market is poised for remarkable expansion as demand for targeted therapies grows and manufacturing technologies advance. With rising investment in R&D, expanding production capacity, and increasing adoption of cutting-edge bioprocessing platforms, the industry is set to play a pivotal role in the future of precision medicine and global healthcare innovation.